KR102745611B1 - 식도 염증 치료를 위한 ecm 하이드로겔 - Google Patents
식도 염증 치료를 위한 ecm 하이드로겔 Download PDFInfo
- Publication number
- KR102745611B1 KR102745611B1 KR1020197026981A KR20197026981A KR102745611B1 KR 102745611 B1 KR102745611 B1 KR 102745611B1 KR 1020197026981 A KR1020197026981 A KR 1020197026981A KR 20197026981 A KR20197026981 A KR 20197026981A KR 102745611 B1 KR102745611 B1 KR 102745611B1
- Authority
- KR
- South Korea
- Prior art keywords
- ecm
- hydrogel
- esophageal
- esophagus
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000017 hydrogel Substances 0.000 title claims abstract description 214
- 206010061218 Inflammation Diseases 0.000 title claims abstract description 40
- 230000004054 inflammatory process Effects 0.000 title claims abstract description 40
- 238000011282 treatment Methods 0.000 title description 33
- 210000002744 extracellular matrix Anatomy 0.000 claims abstract description 289
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims abstract description 287
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims abstract description 287
- 210000003238 esophagus Anatomy 0.000 claims abstract description 83
- 239000000203 mixture Substances 0.000 claims abstract description 51
- 238000001879 gelation Methods 0.000 claims abstract description 34
- 208000023514 Barrett esophagus Diseases 0.000 claims abstract description 29
- 208000023665 Barrett oesophagus Diseases 0.000 claims abstract description 29
- 208000007217 Esophageal Stenosis Diseases 0.000 claims abstract description 13
- 206010030194 Oesophageal stenosis Diseases 0.000 claims abstract description 13
- 210000001519 tissue Anatomy 0.000 claims description 53
- 239000000243 solution Substances 0.000 claims description 29
- 210000003932 urinary bladder Anatomy 0.000 claims description 16
- 210000000813 small intestine Anatomy 0.000 claims description 9
- 108091005508 Acid proteases Proteins 0.000 claims description 8
- 239000000872 buffer Substances 0.000 claims description 8
- 239000003929 acidic solution Substances 0.000 claims description 7
- 102000004142 Trypsin Human genes 0.000 claims description 6
- 108090000631 Trypsin Proteins 0.000 claims description 6
- 239000012588 trypsin Substances 0.000 claims description 6
- 102000057297 Pepsin A Human genes 0.000 claims description 5
- 108090000284 Pepsin A Proteins 0.000 claims description 5
- 230000029087 digestion Effects 0.000 claims description 5
- 229940111202 pepsin Drugs 0.000 claims description 5
- 210000004185 liver Anatomy 0.000 claims description 4
- 210000003491 skin Anatomy 0.000 claims description 4
- 238000007865 diluting Methods 0.000 claims description 3
- 210000005081 epithelial layer Anatomy 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 86
- 230000000670 limiting effect Effects 0.000 abstract description 16
- 230000000694 effects Effects 0.000 abstract description 15
- 208000031481 Pathologic Constriction Diseases 0.000 abstract description 11
- 238000002347 injection Methods 0.000 abstract description 6
- 239000007924 injection Substances 0.000 abstract description 6
- 230000008901 benefit Effects 0.000 abstract description 3
- 239000000499 gel Substances 0.000 description 50
- 241001465754 Metazoa Species 0.000 description 38
- 210000004877 mucosa Anatomy 0.000 description 27
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 17
- 208000036764 Adenocarcinoma of the esophagus Diseases 0.000 description 16
- 206010030137 Oesophageal adenocarcinoma Diseases 0.000 description 16
- 201000010099 disease Diseases 0.000 description 16
- 208000028653 esophageal adenocarcinoma Diseases 0.000 description 16
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 14
- 210000004876 tela submucosa Anatomy 0.000 description 13
- 238000001839 endoscopy Methods 0.000 description 12
- 206010028116 Mucosal inflammation Diseases 0.000 description 11
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical group [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 11
- 239000000463 material Substances 0.000 description 11
- 206010058314 Dysplasia Diseases 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- 230000035882 stress Effects 0.000 description 10
- 241000282472 Canis lupus familiaris Species 0.000 description 9
- 210000002919 epithelial cell Anatomy 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- 201000010927 Mucositis Diseases 0.000 description 8
- 230000001413 cellular effect Effects 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 230000002378 acidificating effect Effects 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 230000010339 dilation Effects 0.000 description 7
- 208000028299 esophageal disease Diseases 0.000 description 7
- 238000001356 surgical procedure Methods 0.000 description 7
- 230000009747 swallowing Effects 0.000 description 7
- 102000004127 Cytokines Human genes 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- 108091005804 Peptidases Proteins 0.000 description 6
- 239000004365 Protease Substances 0.000 description 6
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 238000005299 abrasion Methods 0.000 description 6
- 230000003110 anti-inflammatory effect Effects 0.000 description 6
- 210000002469 basement membrane Anatomy 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 210000000981 epithelium Anatomy 0.000 description 6
- 210000001035 gastrointestinal tract Anatomy 0.000 description 6
- 210000000130 stem cell Anatomy 0.000 description 6
- 230000001954 sterilising effect Effects 0.000 description 6
- 238000004659 sterilization and disinfection Methods 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 206010002091 Anaesthesia Diseases 0.000 description 5
- 102000008186 Collagen Human genes 0.000 description 5
- 108010035532 Collagen Proteins 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 208000025865 Ulcer Diseases 0.000 description 5
- 230000037005 anaesthesia Effects 0.000 description 5
- 230000035605 chemotaxis Effects 0.000 description 5
- 229920001436 collagen Polymers 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 230000033001 locomotion Effects 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 4
- 206010054949 Metaplasia Diseases 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000004888 barrier function Effects 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 238000000227 grinding Methods 0.000 description 4
- -1 laminins Polymers 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000015689 metaplastic ossification Effects 0.000 description 4
- 229960000381 omeprazole Drugs 0.000 description 4
- 230000036407 pain Effects 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 229940126409 proton pump inhibitor Drugs 0.000 description 4
- 239000000612 proton pump inhibitor Substances 0.000 description 4
- 230000008439 repair process Effects 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 206010050171 Oesophageal dysplasia Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000000739 antihistaminic agent Substances 0.000 description 3
- 210000004082 barrier epithelial cell Anatomy 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 230000036760 body temperature Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000004132 cross linking Methods 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 230000004890 epithelial barrier function Effects 0.000 description 3
- 238000002181 esophagogastroduodenoscopy Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 210000002175 goblet cell Anatomy 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000003801 milling Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000001613 neoplastic effect Effects 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 238000002271 resection Methods 0.000 description 3
- 238000002791 soaking Methods 0.000 description 3
- 239000008223 sterile water Substances 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 231100000397 ulcer Toxicity 0.000 description 3
- 230000036269 ulceration Effects 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 108010014258 Elastin Proteins 0.000 description 2
- 102000016942 Elastin Human genes 0.000 description 2
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 2
- 206010015548 Euthanasia Diseases 0.000 description 2
- 229920002683 Glycosaminoglycan Polymers 0.000 description 2
- 208000034991 Hiatal Hernia Diseases 0.000 description 2
- 206010020028 Hiatus hernia Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241000751119 Mila <angiosperm> Species 0.000 description 2
- 238000011887 Necropsy Methods 0.000 description 2
- 206010030216 Oesophagitis Diseases 0.000 description 2
- 102000016611 Proteoglycans Human genes 0.000 description 2
- 108010067787 Proteoglycans Proteins 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- NOSIYYJFMPDDSA-UHFFFAOYSA-N acepromazine Chemical compound C1=C(C(C)=O)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 NOSIYYJFMPDDSA-UHFFFAOYSA-N 0.000 description 2
- 229960005054 acepromazine Drugs 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 239000002975 chemoattractant Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 229920002549 elastin Polymers 0.000 description 2
- 238000010894 electron beam technology Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 230000003628 erosive effect Effects 0.000 description 2
- 208000006881 esophagitis Diseases 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000036571 hydration Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000004968 inflammatory condition Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 210000000111 lower esophageal sphincter Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 208000025402 neoplasm of esophagus Diseases 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 208000000689 peptic esophagitis Diseases 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 238000007634 remodeling Methods 0.000 description 2
- 238000000518 rheometry Methods 0.000 description 2
- 210000005125 simple columnar epithelium Anatomy 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- 208000003200 Adenoma Diseases 0.000 description 1
- 208000000884 Airway Obstruction Diseases 0.000 description 1
- 206010006707 Burn oesophageal Diseases 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010008589 Choking Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010011985 Decubitus ulcer Diseases 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 206010015137 Eructation Diseases 0.000 description 1
- 206010073306 Exposure to radiation Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 208000031361 Hiccup Diseases 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 206010065764 Mucosal infection Diseases 0.000 description 1
- 206010058803 Oesophageal infection Diseases 0.000 description 1
- 206010030201 Oesophageal ulcer Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 208000006994 Precancerous Conditions Diseases 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 206010046555 Urinary retention Diseases 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000008649 adaptation response Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 210000005068 bladder tissue Anatomy 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 1
- 229960001736 buprenorphine Drugs 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 229960001139 cefazolin Drugs 0.000 description 1
- MLYYVTUWGNIJIB-BXKDBHETSA-N cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 description 1
- 230000034303 cell budding Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 229940106164 cephalexin Drugs 0.000 description 1
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000012829 chemotherapy agent Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 210000002777 columnar cell Anatomy 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 230000005106 durotaxis Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 239000002895 emetic Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000012143 endoscopic resection Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000010393 epithelial cell migration Effects 0.000 description 1
- 208000019064 esophageal ulcer Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000002575 gastroscopy Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000024798 heartburn Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 230000002895 hyperchromatic effect Effects 0.000 description 1
- 230000002631 hypothermal effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 238000002647 laser therapy Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 230000003232 mucoadhesive effect Effects 0.000 description 1
- POFWRMVFWIJXHP-UHFFFAOYSA-N n-benzyl-9-(oxan-2-yl)purin-6-amine Chemical compound C=1C=CC=CC=1CNC(C=1N=C2)=NC=NC=1N2C1CCCCO1 POFWRMVFWIJXHP-UHFFFAOYSA-N 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 229920002113 octoxynol Polymers 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 230000005305 organ development Effects 0.000 description 1
- 230000003534 oscillatory effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 238000007539 photo-oxidation reaction Methods 0.000 description 1
- 238000002428 photodynamic therapy Methods 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001855 preneoplastic effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 238000007674 radiofrequency ablation Methods 0.000 description 1
- 230000003134 recirculating effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000036387 respiratory rate Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 235000019614 sour taste Nutrition 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000009772 tissue formation Effects 0.000 description 1
- 210000002438 upper gastrointestinal tract Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762465985P | 2017-03-02 | 2017-03-02 | |
| US62/465,985 | 2017-03-02 | ||
| PCT/US2018/020758 WO2018161028A1 (en) | 2017-03-02 | 2018-03-02 | Ecm hydrogel for treating esophageal inflammation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20190120258A KR20190120258A (ko) | 2019-10-23 |
| KR102745611B1 true KR102745611B1 (ko) | 2024-12-20 |
Family
ID=63371156
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020197026981A Active KR102745611B1 (ko) | 2017-03-02 | 2018-03-02 | 식도 염증 치료를 위한 ecm 하이드로겔 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US11213545B2 (enExample) |
| EP (2) | EP4252842B1 (enExample) |
| JP (3) | JP7203428B2 (enExample) |
| KR (1) | KR102745611B1 (enExample) |
| CN (1) | CN110352061A (enExample) |
| AU (2) | AU2018226867B2 (enExample) |
| CA (1) | CA3052489A1 (enExample) |
| ES (2) | ES3039679T3 (enExample) |
| WO (1) | WO2018161028A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3119448B1 (en) | 2014-03-21 | 2020-04-22 | University of Pittsburgh- Of the Commonwealth System of Higher Education | Methods for preparation of a terminally sterilized hydrogel derived from extracellular matrix |
| EP4268892B1 (en) | 2016-03-02 | 2025-01-29 | University of Pittsburgh- Of the Commonwealth System of Higher Education | Matrix bound nanovesicles and their use |
| ES3039679T3 (en) | 2017-03-02 | 2025-10-23 | Univ Pittsburgh Commonwealth Sys Higher Education | Ecm hydrogel for treating esophageal inflammation |
| EP3589294B1 (en) | 2017-03-02 | 2022-10-26 | University of Pittsburgh - Of the Commonwealth System of Higher Education | Extracellular matrix (ecm) hydrogel and soluble fraction thereof for use in the treatment of cancer |
| ES2945740T3 (es) | 2017-05-05 | 2023-07-06 | Univ Pittsburgh Commonwealth Sys Higher Education | Aplicaciones oculares de vesículas unidas a matriz (MBV) |
| KR20210005942A (ko) | 2018-05-03 | 2021-01-15 | 유니버시티 오브 피츠버그 - 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 | Il-33을 포함하는 매트릭스 결합 소포 (mbvs) 및 그 용도 |
| JP2021529024A (ja) | 2018-06-21 | 2021-10-28 | ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | 食道粘膜下流体クッションとしての細胞外マトリックス（ｅｃｍ）ヒドロゲルの使用 |
| CA3103973A1 (en) * | 2018-06-21 | 2019-12-26 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Use of a urinary bladder ecm hydrogel as an esophageal submucosal fluid cushion |
| AU2019288588B2 (en) * | 2018-06-21 | 2024-06-13 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Extracellular matrix (ECM) hydrogel as a submucosal fluid cushion |
| KR20210142003A (ko) * | 2019-03-13 | 2021-11-23 | 유니버시티 오브 피츠버그 - 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 | 음향 세포외 기질 하이드로겔 및 이의 용도 |
| JP2023514821A (ja) * | 2020-02-28 | 2023-04-11 | テキサス メディカル センター | 癒着阻止および組織治癒向上のための噴霧可能刺激応答性マイクロヒドロゲル |
| EP4230725A4 (en) * | 2020-11-17 | 2025-02-12 | Cellartgen Inc. | ESOPHAGEAL EXTRACELLULAR MATRIX DERIVED SCAFFOLD FOR ESOPHAGEAL ORGANOID CULTURE AND TRANSPLANTATION, AND PRODUCTION METHOD THEREOF |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008109407A2 (en) * | 2007-03-02 | 2008-09-12 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Extracellular matrix-derived gels and related methods |
Family Cites Families (91)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3155095A (en) | 1961-02-07 | 1964-11-03 | Adolph M Brown | Anastomosis method and means |
| US4294241A (en) | 1977-06-09 | 1981-10-13 | Teruo Miyata | Collagen skin dressing |
| US4582640A (en) | 1982-03-08 | 1986-04-15 | Collagen Corporation | Injectable cross-linked collagen implant material |
| US4563350A (en) | 1984-10-24 | 1986-01-07 | Collagen Corporation | Inductive collagen based bone repair preparations |
| US4978668A (en) | 1986-09-02 | 1990-12-18 | Purdue Research Foundation | Treatment to reduce ischemic tissue injury |
| US4956178A (en) | 1988-07-11 | 1990-09-11 | Purdue Research Foundation | Tissue graft composition |
| US4902508A (en) | 1988-07-11 | 1990-02-20 | Purdue Research Foundation | Tissue graft composition |
| US5007927A (en) | 1989-10-24 | 1991-04-16 | Purdue Research Foundation | Muscle-powered cardiac assist device |
| US5281422A (en) | 1991-09-24 | 1994-01-25 | Purdue Research Foundation | Graft for promoting autogenous tissue growth |
| US5354274A (en) | 1992-08-20 | 1994-10-11 | Methodist Hospital Of Indiana, Inc. | Device for oral administration of liquids |
| US5275826A (en) | 1992-11-13 | 1994-01-04 | Purdue Research Foundation | Fluidized intestinal submucosa and its use as an injectable tissue graft |
| US5641518A (en) | 1992-11-13 | 1997-06-24 | Purdue Research Foundation | Method of repairing bone tissue |
| US5352463A (en) | 1992-11-13 | 1994-10-04 | Badylak Steven F | Tissue graft for surgical reconstruction of a collagenous meniscus and method therefor |
| US6653291B1 (en) | 1992-11-13 | 2003-11-25 | Purdue Research Foundation | Composition and method for production of transformed cells |
| ATE219343T1 (de) | 1994-04-29 | 2002-07-15 | Scimed Life Systems Inc | Stent mit kollagen |
| US6475232B1 (en) | 1996-12-10 | 2002-11-05 | Purdue Research Foundation | Stent with reduced thrombogenicity |
| US5695998A (en) | 1995-02-10 | 1997-12-09 | Purdue Research Foundation | Submucosa as a growth substrate for islet cells |
| US6485723B1 (en) | 1995-02-10 | 2002-11-26 | Purdue Research Foundation | Enhanced submucosal tissue graft constructs |
| US5554389A (en) | 1995-04-07 | 1996-09-10 | Purdue Research Foundation | Urinary bladder submucosa derived tissue graft |
| DE69622548T2 (de) | 1995-04-07 | 2003-09-18 | Methodist Health Group, Inc. | Gewebetransplantat zur blasenrekonstruktion |
| US5711969A (en) | 1995-04-07 | 1998-01-27 | Purdue Research Foundation | Large area submucosal tissue graft constructs |
| CA2160647C (en) | 1995-10-16 | 2002-05-28 | Thomas William Garay | Helical bearing anchor catcher |
| US5755791A (en) | 1996-04-05 | 1998-05-26 | Purdue Research Foundation | Perforated submucosal tissue graft constructs |
| BR9711166A (pt) | 1996-08-23 | 1999-08-17 | Cook Biotech Inc | PrÄtese de enxerto materiais para sua prepara-Æo e m-todos para seu uso |
| CA2263898C (en) | 1996-09-16 | 2009-12-08 | Purdue Research Foundation | Composition and method for repairing neurological tissue |
| CA2267449C (en) | 1996-11-05 | 2008-10-14 | Purdue Research Foundation | Myocardial graft constructs |
| TW510803B (en) | 1996-11-20 | 2002-11-21 | Yasuhiko Shimizu | Man-made esophagus and its manufacturing method |
| US6375989B1 (en) | 1996-12-10 | 2002-04-23 | Purdue Research Foundation | Submucosa extracts |
| AU736572B2 (en) | 1996-12-10 | 2001-08-02 | Purdue Research Foundation | Artificial vascular valves |
| WO1998025636A1 (en) | 1996-12-10 | 1998-06-18 | Purdue Research Foundation | Stomach submucosa derived tissue graft |
| CA2274033C (en) | 1996-12-10 | 2010-05-11 | Purdue Research Foundation | Biomaterial derived from vertebrate liver tissue |
| AU743779B2 (en) | 1996-12-10 | 2002-02-07 | Cook Biotech, Inc. | Tubular grafts from purified submucosa |
| US6696270B2 (en) | 1996-12-10 | 2004-02-24 | Purdue Research Foundation | Gastric submucosal tissue as a novel diagnostic tool |
| EP1011699B1 (en) | 1997-09-11 | 2001-12-05 | Purdue Research Foundation | Galactosidase modified submucosal tissue |
| WO1999043786A2 (en) | 1998-02-27 | 1999-09-02 | Purdue Research Foundation | Submucosa gel compositions |
| US6448076B2 (en) | 1998-09-15 | 2002-09-10 | The Regents Of The University Of Michigan | Method for chemically acellularizing a biological tissue sample |
| US6918396B1 (en) | 1998-12-01 | 2005-07-19 | Purdue Research Foundation | Method for vocal cord reconstruction |
| AU759272B2 (en) | 1998-12-01 | 2003-04-10 | Medical College Of Ohio At Toledo | Submucosa modulation of mammalian immune response |
| US6576265B1 (en) | 1999-12-22 | 2003-06-10 | Acell, Inc. | Tissue regenerative composition, method of making, and method of use thereof |
| US6579538B1 (en) | 1999-12-22 | 2003-06-17 | Acell, Inc. | Tissue regenerative compositions for cardiac applications, method of making, and method of use thereof |
| AU2001284968B2 (en) | 2000-08-16 | 2006-12-21 | Duke University | Decellularized tissue engineered constructs and tissues |
| EP1343492B1 (en) * | 2000-11-22 | 2006-02-01 | Rxkinetix, Inc. | Treatment of mucositis |
| AU2003202261A1 (en) | 2002-01-11 | 2003-07-30 | Purdue Research Foundation | Biomaterial derived from vertebrate liver tissue |
| WO2003059284A2 (en) | 2002-01-11 | 2003-07-24 | Purdue Research Foundation | Composition and method for inhibiting hypersensitivity |
| CN1665527A (zh) | 2002-05-02 | 2005-09-07 | 普渡研究基金会 | 血管化增强的移植构造物 |
| CN1713861A (zh) | 2002-05-02 | 2005-12-28 | 普渡研究基金会 | 血管化增强的移植构造物 |
| NZ536563A (en) | 2002-05-02 | 2008-03-28 | Purdue Research Foundation | Vascularization enhanced graft constructs |
| US7402319B2 (en) | 2002-09-27 | 2008-07-22 | Board Of Regents, The University Of Texas System | Cell-free tissue replacement for tissue engineering |
| US20040191226A1 (en) | 2002-12-04 | 2004-09-30 | Badylak Stephen F. | Method for repair of body wall |
| US20040187877A1 (en) | 2002-12-04 | 2004-09-30 | Badylak Stephen F. | Method for repair of liver tissue |
| US20040176855A1 (en) | 2003-03-07 | 2004-09-09 | Acell, Inc. | Decellularized liver for repair of tissue and treatment of organ deficiency |
| US20040175366A1 (en) | 2003-03-07 | 2004-09-09 | Acell, Inc. | Scaffold for cell growth and differentiation |
| AU2004253508A1 (en) | 2003-06-25 | 2005-01-13 | Acell, Inc. | Conditioned matrix compositions for tissue restoration |
| US7326571B2 (en) | 2003-07-17 | 2008-02-05 | Boston Scientific Scimed, Inc. | Decellularized bone marrow extracellular matrix |
| US8021692B2 (en) | 2003-08-25 | 2011-09-20 | Cook Biotech Incorporated | Graft materials containing bioactive substances, and methods for their manufacture |
| US8741352B2 (en) | 2003-08-25 | 2014-06-03 | Cook Biotech Incorporated | Graft materials containing ECM components, and methods for their manufacture |
| KR101084563B1 (ko) | 2004-03-19 | 2011-11-17 | 도요타 지도샤（주） | 자동차용 바이저 |
| US7905826B2 (en) | 2004-11-03 | 2011-03-15 | Cook Incorporated | Methods for modifying vascular vessel walls |
| US8874204B2 (en) | 2004-12-20 | 2014-10-28 | Cardiac Pacemakers, Inc. | Implantable medical devices comprising isolated extracellular matrix |
| US9138445B2 (en) | 2005-03-09 | 2015-09-22 | Cook Biotech Incorporated | Medical graft materials with adherent extracellular matrix fibrous mass |
| WO2007005792A2 (en) | 2005-07-01 | 2007-01-11 | University Of Pittsburgh | Wound healing polymeric networks |
| WO2007084278A2 (en) | 2006-01-06 | 2007-07-26 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Extracellular matrix based gastroesophageal junction reinforcement device |
| US8241908B2 (en) | 2006-05-16 | 2012-08-14 | Becton, Dickinson And Company | Extracellular matrix coated surface for culturing cells |
| WO2008008266A2 (en) | 2006-07-07 | 2008-01-17 | University Of Pittsburgh- Of The Commonwealth System Of Higher Education | Biohybrid elastomeric scaffolds and methods of use thereof |
| CN106390200A (zh) | 2006-10-23 | 2017-02-15 | 库克生物科技公司 | 组分特性增强的处理的ecm材料 |
| US20110184439A1 (en) | 2008-05-09 | 2011-07-28 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Biological Matrix for Cardiac Repair |
| US9277999B2 (en) | 2009-02-27 | 2016-03-08 | University of Pittsburgh—of the Commonwealth System of Higher Education | Joint bioscaffolds |
| WO2011044443A2 (en) | 2009-10-09 | 2011-04-14 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Matricryptic ecm peptides for tissue reconstruction |
| US9814744B2 (en) | 2009-12-22 | 2017-11-14 | University of Pittsburg—Of the Commonwealth System of Higher Education | Decellularized adipose cell growth scaffold |
| WO2012024390A2 (en) | 2010-08-17 | 2012-02-23 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Biohybrid composite scaffold |
| CA2832811A1 (en) | 2011-04-12 | 2012-10-18 | Novo Nordisk A/S | Double-acylated glp-1 derivatives |
| US20140356331A1 (en) | 2011-07-08 | 2014-12-04 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Injectable cns-derived ecm for tissue reconstruction |
| US20140227364A1 (en) | 2013-02-08 | 2014-08-14 | Kimberly A. Kentner | Methods of manufacturing bioactive gels from extracellular matrix material |
| AU2014251110A1 (en) | 2013-04-08 | 2015-11-26 | Regentys Corporation | Method and composition for treating inflammatory bowel disease without colectomy |
| US9861662B2 (en) | 2013-07-03 | 2018-01-09 | University of Pittsburgh—of the Commonwealth System of Higher Education | Bone-derived extra cellular matrix gel |
| ITMI20131924A1 (it) | 2013-11-20 | 2015-05-21 | Cosmo Technologies Ltd | Emulsions or microemulsions for use in endoscopic mucosal resectioning and/or endoscopic submucosal dissection emulsioni o microemulsioni per uso nella resezione mucosale endoscopica e/o dissezione submucosale endoscopica |
| US10286119B2 (en) | 2014-01-24 | 2019-05-14 | University of Pittsburgh—of the Commonwealth System of Higher Education | Extracellular matrix mesh coating |
| EP3119448B1 (en) | 2014-03-21 | 2020-04-22 | University of Pittsburgh- Of the Commonwealth System of Higher Education | Methods for preparation of a terminally sterilized hydrogel derived from extracellular matrix |
| US20170049932A1 (en) | 2014-04-24 | 2017-02-23 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Fractionating Extracellular Matrix to Modulate Bioactivity and the Host Response |
| EP3319653A4 (en) | 2015-07-10 | 2019-03-27 | University of Pittsburgh - Of the Commonwealth System of Higher Education | METHOD FOR PRODUCING ECM EQUIPMENT AND HYDROGELS FROM COLON |
| WO2017044787A1 (en) | 2015-09-10 | 2017-03-16 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Bi-layer extra cellular matrix scaffolds and uses therefor |
| ES2873519T3 (es) | 2015-09-18 | 2021-11-03 | Univ Pittsburgh Commonwealth Sys Higher Education | Matriz extracelular soluble no gelificante con actividad biológica |
| AU2017207015B2 (en) | 2016-01-13 | 2022-08-04 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Vascular extracellular matrix hydrogel |
| EP4268892B1 (en) | 2016-03-02 | 2025-01-29 | University of Pittsburgh- Of the Commonwealth System of Higher Education | Matrix bound nanovesicles and their use |
| CA3017747A1 (en) | 2016-03-14 | 2017-09-21 | Regentys Corporation | Method and composition for treating inflammatory bowel disease |
| EP3589294B1 (en) * | 2017-03-02 | 2022-10-26 | University of Pittsburgh - Of the Commonwealth System of Higher Education | Extracellular matrix (ecm) hydrogel and soluble fraction thereof for use in the treatment of cancer |
| ES3039679T3 (en) | 2017-03-02 | 2025-10-23 | Univ Pittsburgh Commonwealth Sys Higher Education | Ecm hydrogel for treating esophageal inflammation |
| US11389569B2 (en) | 2017-04-03 | 2022-07-19 | University of Pittsburgh—of the Commonwealth System of Higher Education | Biodegradable, porous, thermally responsive injectable hydrogel as soft tissue defect filler |
| ES2945740T3 (es) | 2017-05-05 | 2023-07-06 | Univ Pittsburgh Commonwealth Sys Higher Education | Aplicaciones oculares de vesículas unidas a matriz (MBV) |
| US12329883B2 (en) | 2017-10-24 | 2025-06-17 | Davol Inc. | Soft tissue repair implants comprising hydroxybutyrate |
| KR20210005942A (ko) | 2018-05-03 | 2021-01-15 | 유니버시티 오브 피츠버그 - 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 | Il-33을 포함하는 매트릭스 결합 소포 (mbvs) 및 그 용도 |
-
2018
- 2018-03-02 ES ES23186922T patent/ES3039679T3/es active Active
- 2018-03-02 EP EP23186922.3A patent/EP4252842B1/en active Active
- 2018-03-02 EP EP18760637.1A patent/EP3589292B1/en active Active
- 2018-03-02 US US16/490,054 patent/US11213545B2/en active Active
- 2018-03-02 CN CN201880015258.5A patent/CN110352061A/zh active Pending
- 2018-03-02 JP JP2019547483A patent/JP7203428B2/ja active Active
- 2018-03-02 KR KR1020197026981A patent/KR102745611B1/ko active Active
- 2018-03-02 ES ES18760637T patent/ES2957291T3/es active Active
- 2018-03-02 CA CA3052489A patent/CA3052489A1/en active Pending
- 2018-03-02 AU AU2018226867A patent/AU2018226867B2/en active Active
- 2018-03-02 WO PCT/US2018/020758 patent/WO2018161028A1/en not_active Ceased
-
2021
- 2021-11-12 US US17/525,577 patent/US11707485B2/en active Active
-
2022
- 2022-12-20 JP JP2022202955A patent/JP7681909B2/ja active Active
-
2023
- 2023-07-14 US US18/222,187 patent/US12303533B2/en active Active
-
2024
- 2024-02-01 AU AU2024200617A patent/AU2024200617B2/en active Active
- 2024-11-26 JP JP2024205576A patent/JP2025019254A/ja active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008109407A2 (en) * | 2007-03-02 | 2008-09-12 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Extracellular matrix-derived gels and related methods |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4252842A3 (en) | 2023-10-25 |
| AU2018226867B2 (en) | 2023-11-02 |
| JP2023024578A (ja) | 2023-02-16 |
| CN110352061A (zh) | 2019-10-18 |
| AU2024200617B2 (en) | 2025-10-23 |
| EP4252842A2 (en) | 2023-10-04 |
| US20240189349A1 (en) | 2024-06-13 |
| JP7681909B2 (ja) | 2025-05-23 |
| US20200009187A1 (en) | 2020-01-09 |
| ES2957291T3 (es) | 2024-01-16 |
| US12303533B2 (en) | 2025-05-20 |
| EP3589292A1 (en) | 2020-01-08 |
| KR20190120258A (ko) | 2019-10-23 |
| EP3589292A4 (en) | 2020-12-09 |
| CA3052489A1 (en) | 2018-09-07 |
| JP7203428B2 (ja) | 2023-01-13 |
| US11707485B2 (en) | 2023-07-25 |
| US11213545B2 (en) | 2022-01-04 |
| AU2024200617A1 (en) | 2024-02-22 |
| ES3039679T3 (en) | 2025-10-23 |
| JP2025019254A (ja) | 2025-02-06 |
| AU2018226867A1 (en) | 2019-08-22 |
| EP4252842B1 (en) | 2025-06-25 |
| US20220249549A1 (en) | 2022-08-11 |
| WO2018161028A1 (en) | 2018-09-07 |
| EP3589292B1 (en) | 2023-08-23 |
| JP2020509048A (ja) | 2020-03-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7681909B2 (ja) | 食道の炎症を処置するためのｅｃｍヒドロゲル | |
| JP7412777B2 (ja) | 粘膜下流体クッションとしての細胞外マトリックス（ｅｃｍ）ヒドロゲル | |
| JP2024060076A (ja) | 食道粘膜下流体クッションとしての膀胱ｅｃｍヒドロゲルの使用 | |
| JP2024060075A (ja) | 食道粘膜下流体クッションとしての細胞外マトリックス（ｅｃｍ）ヒドロゲルの使用 | |
| HK40091837A (en) | Ecm hydrogel for treating esophageal inflammation | |
| HK40091837B (en) | Ecm hydrogel for treating esophageal inflammation | |
| HK40012466B (en) | Ecm hydrogel for treating esophageal inflammation | |
| HK40012466A (en) | Ecm hydrogel for treating esophageal inflammation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20190916 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20210302 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20230621 Patent event code: PE09021S01D |
|
| E90F | Notification of reason for final refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Final Notice of Reason for Refusal Patent event date: 20240401 Patent event code: PE09021S02D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20241025 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20241218 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20241218 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration |